Bristol Myers Squibb's Iberdomide Application Receives FDA Priority Review
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 17 2026
0mins
Should l Buy BMY?
Source: seekingalpha
- FDA Priority Review: Bristol Myers Squibb announced that its marketing application for iberdomide, an experimental therapy for multiple myeloma, has received priority review from the FDA, marking a significant advancement in the blood cancer treatment landscape.
- Target Action Date: The FDA has set August 17, 2026, as the target action date for the New Drug Application, a timeline that will directly influence the company's future market strategy and financial performance.
- Clinical Trial Support: The application is backed by data from the ongoing Phase 3 EXCALIBER-RRMM study, aimed at providing new treatment options for patients with relapsed or refractory multiple myeloma, demonstrating the company's continued investment in research and development.
- Disease Response Evaluation: The application focuses on the endpoint related to minimal residual disease (MRD), which has become a critical measure for evaluating treatment response in multiple myeloma, reflecting the company's commitment to clinical efficacy and its competitive positioning in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 56.770
Low
37.00
Averages
55.86
High
68.00
Current: 56.770
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bristol Myers Squibb Partners with Hengrui Pharma for Drug Development
- Significant Partnership: Bristol Myers Squibb has announced a potential multi-billion dollar partnership with Hengrui Pharma, aiming to co-develop around a dozen drugs, including four that Bristol will send to China for early-stage clinical trials, marking a new phase of international collaboration in drug development.
- Shift in R&D Model: This collaboration represents a departure from traditional licensing agreements, as both companies will contribute resources to drug development, positioning China as a vital part of the global pharmaceutical R&D ecosystem and highlighting U.S. drugmakers' increasing focus on the Chinese market.
- Market Trend Shift: According to DealForma, over half of large pharmaceutical licensing deals this year have originated from China, up from 39% last year, indicating a growing trend among U.S. and European biopharmaceutical companies to shift early drug development to China to expedite market entry.
- Future Industry Outlook: Experts predict that early-stage drug discovery will increasingly move to China due to its ability to conduct studies at lower costs and faster timelines, potentially reshaping the U.S. pharmaceutical landscape and encouraging more companies to initiate early clinical trials in China.
See More
Bristol Myers Squibb Partners with Hengrui Pharma for Drug Development
- New Drug Collaboration: Bristol Myers Squibb has announced a potential multi-billion dollar partnership with China's Hengrui Pharma to jointly develop about a dozen drugs, including four experimental drugs that will be sent to China for early clinical trials, marking a new phase in cross-continental drug development.
- Significance of the Chinese Market: According to DealForma, over half of large pharmaceutical companies' licensing deals have originated from China this year, a significant increase from 39% last year, indicating a growing focus of American and European biopharmaceutical companies on the Chinese market, which could accelerate the introduction of new drugs.
- Shift in R&D Model: This partnership not only involves sending experimental drugs to China for development but also positions China as a crucial part of the global R&D ecosystem, reflecting the pharmaceutical industry's recognition of China's innovative capabilities and potentially altering the future landscape of drug development.
- Signal of Industry Transformation: As more companies conduct early drug development in China, industry experts believe this will enhance drug development efficiency and reduce costs, potentially challenging the traditional U.S. early drug discovery model and prompting global pharmaceutical companies to reassess their R&D strategies.
See More
Cerebras IPO Shows Strong Performance
- Cerebras IPO Performance: Cerebras Systems' IPO was priced at $185, reaching a high of $386.34 at opening, and settling at $311.07, indicating strong market interest in its AI chips and likely attracting more investor attention.
- Stock Price Fluctuation: After hours, Cerebras' stock rose by 5% to nearly $330, reflecting investor optimism about its growth potential and confidence in the company's valuation amidst a competitive landscape.
- Market Reaction: CNBC's Jim Cramer noted that the timing of this IPO was impeccable, with investors' decisions at current valuations showcasing confidence in the company's future, potentially paving the way for more similar IPOs.
- SpaceX Governance Risks: Concerns about SpaceX's IPO governance structure, including super voting shares and mandatory arbitration for shareholder claims, may deter long-term investors, impacting its market performance and raising questions about transparency and accountability.
See More
Tempus Partners with Bristol Myers Squibb to Optimize Clinical Trials
- Collaboration Goals: Tempus AI's partnership with Bristol Myers Squibb aims to leverage AI and multimodal real-world data to optimize clinical trial designs and enhance the Probability of Technical & Regulatory Success (PTRS) across five initial clinical trial programs, which is expected to significantly improve drug development efficiency.
- Data-Driven Decisions: Utilizing Tempus' Lens platform, the collaboration will analyze a vast library of de-identified multimodal records to delve deeper into patient biology, helping to identify patient segments most likely to benefit from investigational therapies, thereby increasing the success rate of clinical research.
- Oncology and Neuroscience Focus: This initiative not only targets solid tumors such as lung, colon, and prostate cancers but also extends into Alzheimer's disease drug development, showcasing the versatility of Tempus' multimodal database across multiple therapeutic areas.
- Ongoing Innovation: The initiative builds upon existing collaboration between Tempus and BMS, further advancing the Next Pathways program across 13 community health systems to address care gaps for patients with advanced non-small cell lung cancer (aNSCLC).
See More
Ten-Year Review: Lessons from Five Winning Stocks
- Investment Review: On May 4, 2016, David Gardner selected five stocks aimed at navigating an increasingly complex thinking economy; however, ten years later, the overall performance failed to surpass the S&P 500, which rose 249.6% during the same period.
- Celgene's Poor Performance: Celgene was acquired by Bristol Myers Squibb in 2019 for $108.24, achieving only a 7.3% return over ten years, significantly lagging behind the market's 51.6% gain, indicating limited growth opportunities within a large pharmaceutical company.
- Disney's Strategic Shift: Although Disney was selected at a price of $103.67 in 2016, its stock price is nearly flat a decade later, reflecting challenges faced during its transition to streaming, resulting in a disappointing return of -251%.
- Twitter's Successful Acquisition: Twitter was selected at $14.84 in 2016 and was acquired for $54 in 2022, yielding a 263.9% return, showcasing its strong influence and value in the social media landscape.
See More
Novo Nordisk and Hengrui Pharma Form Partnership
- Novo Nordisk Strong Performance: Novo Nordisk's stock rose 2.11% in premarket trading after announcing that patients responding early to its 7.2 mg obesity therapy Wegovy lost more weight over 72 weeks compared to those on the standard 2.4 mg dose, indicating the drug's long-term weight loss potential and strengthening its position in the competitive weight loss market.
- Broadcom Price Target Increase: Broadcom's stock fell 1.50% in premarket trading, despite Citi raising its price target from $475 to $500 while maintaining a Buy rating, with analysts noting that the deal with Anthropic could enhance gross margins, reflecting market optimism about its future financial performance.
- Alphabet Faces Security Challenges: Alphabet's stock declined 1.00% in premarket trading after its Threat Intelligence Group reported successfully thwarting an attempt by hackers to exploit vulnerabilities using AI models, highlighting ongoing cybersecurity challenges that could impact market trust in the company.
- Bristol Myers and Hengrui Pharma Partnership: Bristol Myers Squibb's stock edged up 0.36% in premarket trading following its announcement of a global partnership with China's Hengrui Pharma worth up to $15.2 billion to jointly advance up to 13 R&D programs in oncology, hematology, and immunology, showcasing the company's potential for international market expansion.
See More
Bristol Myers Squibb Partners with Hengrui Pharma for Drug Development
- Significant Partnership: Bristol Myers Squibb has announced a potential multi-billion dollar partnership with Hengrui Pharma, aiming to co-develop around a dozen drugs, including four that Bristol will send to China for early-stage clinical trials, marking a new phase of international collaboration in drug development.
- Shift in R&D Model: This collaboration represents a departure from traditional licensing agreements, as both companies will contribute resources to drug development, positioning China as a vital part of the global pharmaceutical R&D ecosystem and highlighting U.S. drugmakers' increasing focus on the Chinese market.
- Market Trend Shift: According to DealForma, over half of large pharmaceutical licensing deals this year have originated from China, up from 39% last year, indicating a growing trend among U.S. and European biopharmaceutical companies to shift early drug development to China to expedite market entry.
- Future Industry Outlook: Experts predict that early-stage drug discovery will increasingly move to China due to its ability to conduct studies at lower costs and faster timelines, potentially reshaping the U.S. pharmaceutical landscape and encouraging more companies to initiate early clinical trials in China.
See More
Bristol Myers Squibb Partners with Hengrui Pharma for Drug Development
- New Drug Collaboration: Bristol Myers Squibb has announced a potential multi-billion dollar partnership with China's Hengrui Pharma to jointly develop about a dozen drugs, including four experimental drugs that will be sent to China for early clinical trials, marking a new phase in cross-continental drug development.
- Significance of the Chinese Market: According to DealForma, over half of large pharmaceutical companies' licensing deals have originated from China this year, a significant increase from 39% last year, indicating a growing focus of American and European biopharmaceutical companies on the Chinese market, which could accelerate the introduction of new drugs.
- Shift in R&D Model: This partnership not only involves sending experimental drugs to China for development but also positions China as a crucial part of the global R&D ecosystem, reflecting the pharmaceutical industry's recognition of China's innovative capabilities and potentially altering the future landscape of drug development.
- Signal of Industry Transformation: As more companies conduct early drug development in China, industry experts believe this will enhance drug development efficiency and reduce costs, potentially challenging the traditional U.S. early drug discovery model and prompting global pharmaceutical companies to reassess their R&D strategies.
See More
Cerebras IPO Shows Strong Performance
- Cerebras IPO Performance: Cerebras Systems' IPO was priced at $185, reaching a high of $386.34 at opening, and settling at $311.07, indicating strong market interest in its AI chips and likely attracting more investor attention.
- Stock Price Fluctuation: After hours, Cerebras' stock rose by 5% to nearly $330, reflecting investor optimism about its growth potential and confidence in the company's valuation amidst a competitive landscape.
- Market Reaction: CNBC's Jim Cramer noted that the timing of this IPO was impeccable, with investors' decisions at current valuations showcasing confidence in the company's future, potentially paving the way for more similar IPOs.
- SpaceX Governance Risks: Concerns about SpaceX's IPO governance structure, including super voting shares and mandatory arbitration for shareholder claims, may deter long-term investors, impacting its market performance and raising questions about transparency and accountability.
See More
Tempus Partners with Bristol Myers Squibb to Optimize Clinical Trials
- Collaboration Goals: Tempus AI's partnership with Bristol Myers Squibb aims to leverage AI and multimodal real-world data to optimize clinical trial designs and enhance the Probability of Technical & Regulatory Success (PTRS) across five initial clinical trial programs, which is expected to significantly improve drug development efficiency.
- Data-Driven Decisions: Utilizing Tempus' Lens platform, the collaboration will analyze a vast library of de-identified multimodal records to delve deeper into patient biology, helping to identify patient segments most likely to benefit from investigational therapies, thereby increasing the success rate of clinical research.
- Oncology and Neuroscience Focus: This initiative not only targets solid tumors such as lung, colon, and prostate cancers but also extends into Alzheimer's disease drug development, showcasing the versatility of Tempus' multimodal database across multiple therapeutic areas.
- Ongoing Innovation: The initiative builds upon existing collaboration between Tempus and BMS, further advancing the Next Pathways program across 13 community health systems to address care gaps for patients with advanced non-small cell lung cancer (aNSCLC).
See More
Ten-Year Review: Lessons from Five Winning Stocks
- Investment Review: On May 4, 2016, David Gardner selected five stocks aimed at navigating an increasingly complex thinking economy; however, ten years later, the overall performance failed to surpass the S&P 500, which rose 249.6% during the same period.
- Celgene's Poor Performance: Celgene was acquired by Bristol Myers Squibb in 2019 for $108.24, achieving only a 7.3% return over ten years, significantly lagging behind the market's 51.6% gain, indicating limited growth opportunities within a large pharmaceutical company.
- Disney's Strategic Shift: Although Disney was selected at a price of $103.67 in 2016, its stock price is nearly flat a decade later, reflecting challenges faced during its transition to streaming, resulting in a disappointing return of -251%.
- Twitter's Successful Acquisition: Twitter was selected at $14.84 in 2016 and was acquired for $54 in 2022, yielding a 263.9% return, showcasing its strong influence and value in the social media landscape.
See More
Novo Nordisk and Hengrui Pharma Form Partnership
- Novo Nordisk Strong Performance: Novo Nordisk's stock rose 2.11% in premarket trading after announcing that patients responding early to its 7.2 mg obesity therapy Wegovy lost more weight over 72 weeks compared to those on the standard 2.4 mg dose, indicating the drug's long-term weight loss potential and strengthening its position in the competitive weight loss market.
- Broadcom Price Target Increase: Broadcom's stock fell 1.50% in premarket trading, despite Citi raising its price target from $475 to $500 while maintaining a Buy rating, with analysts noting that the deal with Anthropic could enhance gross margins, reflecting market optimism about its future financial performance.
- Alphabet Faces Security Challenges: Alphabet's stock declined 1.00% in premarket trading after its Threat Intelligence Group reported successfully thwarting an attempt by hackers to exploit vulnerabilities using AI models, highlighting ongoing cybersecurity challenges that could impact market trust in the company.
- Bristol Myers and Hengrui Pharma Partnership: Bristol Myers Squibb's stock edged up 0.36% in premarket trading following its announcement of a global partnership with China's Hengrui Pharma worth up to $15.2 billion to jointly advance up to 13 R&D programs in oncology, hematology, and immunology, showcasing the company's potential for international market expansion.
See More
